| CA: Schedule II
DE: Anlage II (Prohibited)
Illegal in Sweden and Louisiana|
AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. It was originally developed by Pfizer which described the compound in a patent in 2009, but was later abandoned and never tested on humans.
On July 12, 2016 the New York City Emergency Medical Services (EMS) responded to a "mass casualty event" in Brooklyn, New York, where 33 people ranging in age from 25 to 59 years old were adversely affected by the drug. 18 were hospitalized. All of the victims were described by by-standers as “zombielike” and the cause was attributed to use of AMB-FUBINACA as the demethylated metabolite was found in the blood and urine of eight of the hospitalized patients that had been sent for testing by the DEA. Screening for the more usual drugs of abuse was negative in all 8 patients. AMB-FUBINACA itself was found in a sample from the product smoked by another patient. The metabolite was identified after 10 days and the AMB-FUBINACA was only confirmed 17 days after the incident.
The state of Louisiana banned AMB-FUBINACA through an emergency rule after it was detected in a synthetic cannabis product called "Train Wreck 2" which had been linked to adverse events and seizures on 3 June 2014.
Sweden's public health agency suggested classifying AMB-FUBINACA as a hazardous substance on November 10, 2014.